Humana (NYSE:HUM) Stock Rating Lowered by Bank of America

Humana (NYSE:HUM) was downgraded by stock analysts at Bank of America from a “neutral” rating to an “underperform” rating in a research report issued to clients and investors on Wednesday, MarketBeat reports. They currently have a $247.00 price target on the insurance provider’s stock, down from their prior price target of $376.00. Bank of America‘s price objective points to a potential upside of 2.18% from the company’s previous close.

HUM has been the topic of several other reports. Piper Sandler began coverage on Humana in a research note on Wednesday, June 26th. They set an “overweight” rating and a $392.00 target price on the stock. Leerink Partners downgraded shares of Humana from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $400.00 to $250.00 in a research note on Wednesday. TD Cowen raised their price target on shares of Humana from $396.00 to $407.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Royal Bank of Canada upped their price objective on Humana from $385.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, September 5th. Finally, JPMorgan Chase & Co. upped their price target on Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a report on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $360.86.

Humana Price Performance

Humana stock opened at $241.72 on Wednesday. The stock has a market cap of $29.13 billion, a price-to-earnings ratio of 15.05, a PEG ratio of 2.44 and a beta of 0.50. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. The business has a 50-day simple moving average of $340.75 and a 200 day simple moving average of $342.90. Humana has a 52 week low of $213.31 and a 52 week high of $530.54.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping the consensus estimate of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The company had revenue of $29.54 billion during the quarter, compared to analyst estimates of $28.52 billion. During the same quarter in the previous year, the firm earned $8.94 earnings per share. Humana’s revenue was up 10.4% on a year-over-year basis. On average, research analysts forecast that Humana will post 16.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Humana

Several institutional investors have recently made changes to their positions in the company. CarsonAllaria Wealth Management Ltd. lifted its stake in shares of Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after buying an additional 39 shares in the last quarter. Hantz Financial Services Inc. acquired a new stake in Humana in the 2nd quarter valued at about $35,000. Family Firm Inc. purchased a new position in Humana in the 2nd quarter worth approximately $37,000. Hollencrest Capital Management acquired a new position in shares of Humana during the 2nd quarter worth approximately $40,000. Finally, Riverview Trust Co purchased a new position in Humana during the second quarter worth approximately $44,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.